A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803

Single-Blind, Randomized, Comparative, Phase I Study to Evaluate the Tolerability, Safety, and Pharmacokinetic Characteristics of Human Chorionic Gonadotropin Between Two Recombinant hCG Products, DA-3803 Injection and Ovidrel Liquid Injection, in Healthy Subjects

This is a single-blind, randomized, comparative, phase I study to evaluate the tolerability, safety and pharmacokinetic characteristics of human chorionic gonadotropin between two recombinant hCG products named DA-3803 injection and ovidrel liquid injection, in healthy subjects. The subjects will injected with these two injections at the the 21day-interval of time and their conditions including vital signs, blood, clinical examination will be carefully observed.

Inclusion Criteria:

• No medical history relating to the alimentary system, liver system, heart system, haematological disease
• Ideal body weight +/- 20%

Exclusion Criteria:

• acute disease within 28 days
• medical history that might affect the absorption, distribution, secretion, metabolism of drugs
• metrectomy surgery
• desexualization
• tubal ligation
• menopause
• pregnancy
• not able to use contraception
• drink alcohol more than 14 units/week
• smoker who smokes 10 or more cigarettes